3-(1-Methyl-4-piperidinyloxy)pyridine | 310880-85-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(1-Methyl-4-piperidinyloxy)pyridine
• 英文别名: 3-(1-methylpiperidin-4-yl)oxypyridine
• CAS: 310880-85-4
• 化学式: C₁₁H₁₆N₂O
• 分子量: 192.261
• InChiKey: JZWNCEPWYHFBAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  25.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-甲基-4-哌啶醇 、 3-羟基吡啶 、 偶氮二甲酸二乙酯 在 盐酸 、 三苯基膦 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 生成 3-(1-Methyl-4-piperidinyloxy)pyridine
  参考文献：
  名称：

  PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

  摘要：

  对于容易受到或患有中枢神经系统疾病等疾病和疾患的患者，可以通过给予需要的患者芳氧烷胺和芳硫烷胺来进行治疗，包括吡啶氧烷胺、苯氧基胺、吡啶硫胺和苯硫胺。示例化合物包括(2-(5-溴(3-吡啶硫))乙基)甲胺，(2-(5-溴(3-吡啶硫))异丙基)甲胺，(2-(5-溴(3-吡啶硫))丙基)甲胺，(3-(5-溴(3-吡啶硫))丙基)甲胺，3-((3S)-3-吡啶氧)吡啶，3-(4-哌啶氧)吡啶，3-(1-甲基-4-哌啶氧)吡啶，(3-苯并[3,4-d]1,3-二氧杂环戊-5-氧丙基)甲胺和甲基(3-三环[7.3.1.0<5,13>]十三烷-2-氧丙基)胺。

  公开号：

  US20010031771A1

文献信息

• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071454A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。
• Pharmaceutical compositions and methods for use
  申请人：Targacept, Inc.

  公开号：US06627648B1

  公开（公告）日：2003-09-30

  Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines and arylthioalkylamines, including pyridyloxyl-alkylamines, phenoxyalkylamines, pyridylthiolalkylamines and phenylthio-alkylamines. Exemplary compounds include (2-(5-bromo(3-pyridylthio))-ethyl)methylamine, (2-(5-bromo(3-pyridylthio))isopropyl)methylamine, (2-(5-bromo(3-pyridylthio))propyl)methylamine, (3-(5-bromo(3-pyridylthio))-propyl)methylamine, 3-((3S)-3-pyrrolidinyloxy)pyridine, 3-(4-piperidinyloxy)pyridine, 3-(1-methyl-4-piperidinyloxy)pyridine, (3-benzo[3,4-d]1,3-dioxolan-5-yloxypropyl)methylamine, and methyl(3-tricyclo[7.3.1.0<5,13>]tridec-2-yloxypropyl)amine.

  患有或易感染中枢神经系统疾病等疾病和疾病的患者，通过向需要此类治疗的患者施用芳氧基烷胺和芳硫基烷胺来治疗。这些化合物包括吡啶氧基烷胺、苯氧基烷胺、吡啶硫基烷胺和苯硫基烷胺。示例化合物包括（2-（5-溴（3-吡啶硫基））-乙基）甲基胺，（2-（5-溴（3-吡啶硫基））异丙基）甲基胺，（2-（5-溴（3-吡啶硫基））丙基）甲基胺，（3-（5-溴（3-吡啶硫基））-丙基）甲基胺，3-（（3S）-3-吡咯烷氧基）吡啶，3-（4-哌啶氧基）吡啶，3-（1-甲基-4-哌啶氧基）吡啶，（3-苯并[3,4-d]1,3-二氧杂环戊基）甲基胺和甲基（3-三环[7.3.1.0<5,13>]十三烷-2-氧基丙基）胺。
• 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
  申请人：Cid-Nunez Jose Maria

  公开号：US20120184525A1

  公开（公告）日：2012-07-19

  The present invention relates to novel triazolo[4,3- a ]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及一种新型的三唑并[4,3-a]吡啶衍生物，其化学式为（I），其中所有基团均如权利要求中所定义。本发明中的化合物是代谢型谷氨酸受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体的mGluR2亚型的疾病。本发明还涉及包含这些化合物的制药组合物，制备这些化合物和组合物的过程，以及使用这些化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病的方法。
• 1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20150141403A1

  公开（公告）日：2015-05-21

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及一种新型的三唑并[4,3-a]吡啶衍生物，其化学式为（I），其中所有基团如权利要求所定义。本发明的化合物是代谢型谷氨酸受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体亚型mGluR2的疾病。本发明还涉及包含这种化合物的制药组合物、制备这种化合物和组合物的过程，以及使用这种化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病的方法。
• AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP2206707B1

  公开（公告）日：2014-07-23